34 yr old previously grade 3 fatty liver now after 1 yr with this scan, diagnosis and management
Reading File
Finding Sources
Finding Sources
Searching PubMed
FibroScan CAP controlled attenuation parameter steatosis grading MASLD
Finding Sources
Finding Sources
Searching PubMed
FibroScan liver stiffness fibrosis MASLD NAFLD management
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching the Web
FibroScan CAP 254 dB/m steatosis grade liver stiffness 5.1 kPa fibrosis stage interpretation 2024 2025
Now I have all the information needed for a thorough, well-referenced answer.
FibroScan Result Interpretation - Dr. Prashanth, 34 yr, Tippu Sultan
Reading the Scan
| Parameter | Result | Reliability | Interpretation |
|---|---|---|---|
| Liver Stiffness (E) | 5.1 kPa (median) | IQR/med 12% (excellent, <30%) | F0-F1 - No to minimal fibrosis |
| CAP Score | 254 dB/m (mean, SD 8) | 10/10 valid shots | S1 - Mild steatosis (11-33% liver involvement) |
| Probe | M probe | Both SmartExam and Guided VCTE confirmed valid | Reliable study |
Diagnosis
MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) - IMPROVED
This patient had grade 3 (severe) steatosis on ultrasound previously (>67% liver involvement). The current FibroScan shows:
-
Steatosis: S1 (CAP 254 dB/m) - The standard cutoff table is:
- S1: 238-260 dB/m (11-33% fatty change)
- S2: 260-290 dB/m (34-66%)
- S3: >290 dB/m (>67%)
At 254 dB/m, this is borderline S1 - a major improvement from prior grade 3 (S3 equivalent). -
Fibrosis: F0-F1 (LSM 5.1 kPa) - Liver stiffness <6 kPa = normal/no significant fibrosis (Harrison's 22E). This is reassuring - despite 1 year of severe fatty liver, no significant fibrosis has developed (no cirrhosis pathway currently active).
-
Excellent scan quality: 10/10 valid shots, IQR/med 12% (well below the <30% reliability threshold).
Interpretation: Significant regression of hepatic steatosis from severe (grade 3/S3) to mild (S1) with no meaningful fibrosis - this is a very positive outcome.
Differential to Keep in Mind
- MASLD (most likely - metabolic risk factors: 34 yr, young)
- Exclude alcohol-related liver disease (ALD) if alcohol intake is present - cutoffs for ALD fibrosis differ slightly
- Consider metabolic comorbidities: obesity, T2DM, dyslipidemia, hypertension, MetS
Management
1. Reinforce What Worked
The regression from grade 3 to S1 steatosis strongly suggests lifestyle intervention has been effective. Identify and maintain whatever behavioral change the patient implemented (weight loss, dietary change, exercise).
2. Lifestyle Optimization (First-line, cornerstone)
- Weight loss: Target 7-10% body weight reduction - this reduces steatosis and halts progression
- Diet: Mediterranean-style diet; reduce refined carbohydrates, saturated fats, sugary drinks, and ultra-processed foods
- Exercise: 150-300 min/week moderate aerobic activity; resistance training independently improves liver fat
- Alcohol: Complete avoidance - even moderate alcohol accelerates fibrosis in steatotic liver
- Fructose/sugar: Restrict high-fructose corn syrup, fruit juices, soft drinks
3. Metabolic Risk Factor Control
| Risk Factor | Target |
|---|---|
| BMI | < 25 (ideally); at minimum >7% weight loss |
| HbA1c (if diabetic) | < 7% |
| LDL cholesterol | Per CV risk profile |
| Hypertension | < 130/80 mmHg |
| Triglycerides | < 150 mg/dL |
4. Pharmacotherapy Considerations (2025-2026 update)
- Resmetirom (Rezdiffra) - FDA-approved March 2024 for MASH (metabolic steatohepatitis) with F2-F3 fibrosis. NOT indicated here as fibrosis is F0-F1.
- GLP-1 RA (semaglutide, liraglutide): Consider if comorbid obesity/T2DM - semaglutide has shown significant steatosis regression in MASH trials. Can be considered even in this patient if BMI warrants it.
- Pioglitazone: Beneficial in NASH with fibrosis - not a priority at F0-F1 without T2DM.
- Vitamin E: Consider in non-diabetic NASH - limited evidence, generally reserved for biopsy-proven NASH.
- Statins: Safe in MASLD, use per cardiovascular risk - do NOT avoid due to elevated LFTs in fatty liver.
5. Monitoring Plan
| Test | Frequency |
|---|---|
| Repeat FibroScan (LSM + CAP) | Every 12-24 months |
| LFTs (AST, ALT, GGT) | Every 6 months |
| FIB-4 score (age, AST, ALT, platelets) | Every 12 months |
| Metabolic panel (lipids, glucose/HbA1c) | Every 6-12 months |
| Liver ultrasound | Annually (if LSM rises or metabolic worsening) |
| HCC surveillance | NOT yet needed - only indicated in cirrhosis (F4) or established MASH with F3+ fibrosis per some guidelines |
6. When to Escalate
- If future FibroScan shows LSM >8 kPa (advanced fibrosis ≥F3) → hepatology referral, consider liver biopsy
- If LSM >12.5 kPa → probable cirrhosis → begin HCC surveillance (6-monthly USS ± AFP), variceal screening
- If CAP rises back to >290 dB/m with metabolic worsening → intensify lifestyle/pharmacotherapy
Summary
| Previous | Now | |
|---|---|---|
| Steatosis | Grade 3 (severe, S3 equivalent) | S1 (mild) - IMPROVED |
| Fibrosis | Unknown | F0-F1 - No significant fibrosis |
| Trend | Severe fatty liver | Significant regression |
Bottom line: Excellent response to treatment. Continue lifestyle modifications, address metabolic risk factors, repeat FibroScan in 12-24 months. No pharmacotherapy specifically for liver disease is required at this stage unless metabolic comorbidities (obesity, T2DM) indicate GLP-1 RA.
Sources: Harrison's Principles of Internal Medicine 22E (2025); FibroScan standard CAP/LSM interpretation tables; MASLD management guidelines (EASL/AASLD)
This is a shared conversation. Sign in to Orris to start your own chat.